Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0873 2% · 1 trial · 2 indications
Each lesion was evaluated for 3 components: erythema, induration, and scaling. Each component was given a score using the following scale: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked, with increasing score reflecting increased lesion severity. The TLS score (range 0 to 12) is calculated as the sum of the 3 components.
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D. |
| Treatment Sequence 2 | EXPERIMENTAL | Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D. |
| Treatment Sequence 3 | EXPERIMENTAL | Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D. |
| Treatment Sequence 4 | EXPERIMENTAL | Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D. |
| Treatment Sequence 5 | EXPERIMENTAL | Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D. |
| Treatment Sequence 6 | EXPERIMENTAL | Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D. |
| Treatment Sequence 7 | EXPERIMENTAL | Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D. |
| Treatment Sequence 8 | EXPERIMENTAL | Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D. |
| Name | Type | Description |
|---|---|---|
| MK-0873 2% Cream | DRUG | Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area. |
| MK-0873 vehicle (placebo) Cream | DRUG | Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area. |
| Calcitriol Cream | DRUG | Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area |
Inclusion Criteria * Is a male or female 18 to 65 years of age * Female subjects of reproductive potential must have a negative serum pregnancy test at screening and agree to use and/or have their partner use two (2) acceptable methods of birth control * Has a Body Mass Index (BMI) ≤36 kg/m\^2 (up ...
MK-0873 2% is an investigational small molecule being developed for the treatment of plaque psoriasis, a form of psoriasis. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its efficacy and pharmacokinetics in patients with this condition.
MK-0873 2% is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in treating plaque psoriasis.
MK-0873 2% is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 trial has been completed, and the drug remains under investigation for the treatment of plaque psoriasis.
MK-0873 2% has been studied in one completed Phase 1 clinical trial, identified as NCT01235728. This trial, titled "A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)," enrolled 24 participants in the United States. The study was randomized, double-blind, and controlled.
MK-0873 2% is a specific formulation or concentration of the investigational drug MK-0873. The 2% designation refers to the concentration of the active ingredient in the formulation being studied. The clinical trial NCT01235728 evaluates this 2% formulation for the treatment of plaque psoriasis.